February 26, 2019

Dear Advocacy Partner,

Mallinckrodt Pharmaceuticals provided an update on VTS-270, our developmental drug intended for the treatment of patients with Niemann-Pick Type C, during our Investor Relations call today. We expect a submission discussion with FDA in late Spring. Patients continue to receive VTS-270 in the open label portion of the pivotal study and through compassionate use, and we look forward to hearing the learnings from the Patient-Focused Drug Development meeting of patients, caregivers, patient advocacy organizations and the FDA, scheduled next month.

We appreciate your interest and ongoing support as we continue to analyze the totality of the clinical data of VTS-270 and deepen our understanding of NPC. Mallinckrodt remains deeply committed to our work in this area and we will continue to stay in touch with you – and your communities – to provide updates on our progress. We invite you to share these updates with your community as you deem appropriate. The patients, healthcare professionals and caregivers you work with every day have played an important role in Mallinckrodt's commitment to the development of VTS-270 and we are grateful for their ongoing support.

I also wanted to share with you our celebration of the upcoming Rare Disease Week, culminating in some special events for Rare Diseases Day. Mallinckrodt proudly partners with the National Organization for Rare Disorders (NORD) Rare Disease Day on February 28th, a day designated to raise awareness for rare diseases and their impact on patients' lives. I look forward to our continued engagement. Please feel free to contact me with any questions.

Regards,

Sheila Talafous
Director, Advocacy Relations
sheila.talafous@mnk.com